Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,121 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

NCT01846390

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada
  • Regional Health Authority B, Zone 2 Saint John, New Brunswick, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
View Trial Details
Completed

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

NCT05068440

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital Hefei, Anhui, China
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • Sun Yat Sen University Cancer Center Guangzhou, Guangdong, China
View all 25 locations
View Trial Details
Completed

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

NCT05962606

Conditions
Community-Acquired Infections, Community-Acquired Pneumonia, Hemic and Lymphatic Diseases, +14 more
Locations
  • University of Alabama at Birmingham Heersink School of Medicine Birmingham, Alabama, United States
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • Clinique Saint Pierre Ottignies, Belgium
  • Centre Hospitalier Argenteuil Argenteuil, France
View all 27 locations
View Trial Details
Completed

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

NCT02601313

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Banner MD Anderson Gilbert, Arizona, United States
  • City of Hope Duarte, California, United States
  • University California Los Angeles (UCLA) Santa Monica, California, United States
  • Stanford University Stanford, California, United States
View all 32 locations
View Trial Details

Related conditions